Related Experiment Video
Updated: Aug 9, 2026

Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
[Natriuretic peptides in heart failure]
M Emdin1, R Poletti, A Giannoni
1U.O. Medicina Cardiovascolare, Istituto di Fisiologia Clinica del CNR, Pisa. emdin@ifc.cnr.it
Abstract:
The recent discovery of cardiac endocrine function, together with the development of accurate and feasible assay methods for cardiac natriuretic hormone evaluation, i.e. for B-type natriuretic peptide (BNP) and inactive peptide NT-proBNP have confirmed their pathophysiological and clinical significance for cardiovascular disease assessment. Concerning heart failure, their value is for diagnostic screening in selected/unselected populations, for differential diagnosis of dyspnea and for prognostic stratification, and as a guide for follow-up and treatment of patients. Recent Italian recommendations pointed out that BNP/NT-proBNP has a role in ruling-out the diagnosis of heart failure in patients with dubious signs/symptoms: plasma BNP/NT-proBNP concentrations help in the clinical evaluation of chronic heart failure patients when risk stratification is needed, whereas the routine BNP/NT-proBNP assay is still not recommended to guide therapeutic decision-making.
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Heart Failure V: Medical Management
Heart Failure Drugs: β-Blockers
